bioMérieux Showcases Diagnostic Innovation and AMR Leadership at ADLM 2025
bioMérieux reaffirmed its role as the global leader in infectious disease diagnostics and antimicrobial resistance (AMR) advocacy at the 2025 Association for Diagnostics & Laboratory Medicine (ADLM) Scientific Meeting and Clinical Lab Expo.
Our presence at this premier industry event in Chicago underscored our commitment to driving awareness, education, and action through innovation and collaboration.
As part of our mission to combat AMR, we leveraged the ADLM platform to spotlight our significant R&D investments and cutting-edge diagnostic solutions. These innovations are designed to support stewardship efforts and empower clinical and policy stakeholders across both inpatient and outpatient care settings.
Our booth experience was thoughtfully designed to educate and engage. Visitors explored a dynamic space that combined impactful storytelling, digital interaction, and hands-on product demonstrations — all aimed at deepening understanding of how diagnostics can transform patient outcomes and public health.
bioMerieux's booth at ADLM (Jean-Marc Giboux/AP Content Services for bioMérieux)
We also hosted two well-attended symposia:
- From Cough to Critical: The Role of Syndromic Respiratory Testing Across the Care Continuum
- An Integrated Diagnostics Approach in the Fight Against Antimicrobial Resistance: Unlocking Clinical, Economic, and Operational Value
These sessions highlighted the clinical and operational value of diagnostics in real-world settings, reinforcing our commitment to delivering solutions that matter.
A key moment at ADLM 2025 was our press briefing, “The Urgent Need to Fight Antimicrobial Resistance with Diagnostics.” The panel featured Jennifer Zinn, Executive Vice President of Clinical Operations, alongside John Osiecki, Ph.D., Vice President of Medical Affairs, North America, and Rachel Goodman, M.D., a Chicago-area pediatrician. Together, they addressed the growing threat of AMR—projected to surpass cancer as the leading cause of death globally by 2050—and emphasized the critical role diagnostics play in reducing unnecessary antibiotic use.
“Diagnostics are the first line of defense in protecting public health. From detecting outbreaks to informing patient treatment decisions; from protecting consumers through pharmaceutical and food safety. Our technologies enable fast, precise responses to our most pressing health threats,” said Jennifer Zinn. “As the world evolves and healthcare continues to transform, we recognize the urgency to stay ahead of what’s next. Diagnostics must lead that change.
Because the future of healthcare depends on our ability to detect, respond, and prevent—before it’s too late.”
bioMérieux hosts press briefing on the importance of diagnostics in fighting AMR. (Jean-Marc Giboux/AP Content Services for bioMérieux)
With more than 2.8 million Americans affected by drug-resistant infections each year, and more than 35,000 deaths, the need for action is urgent. Diagnostics can reduce inappropriate antibiotic use by up to 36%, offering a powerful yet underutilized tool in the fight against AMR.
We thank all who visited our booth and joined the conversation. We hope you left informed, inspired, and empowered to take action in the global fight against antimicrobial resistance.
Learn more about our press briefing, discussion, and how you can take part in our AMR initiatives here.
